Advertisement

Valproate-induced rest tremor and parkinsonism

  • José Fidel Baizabal-CarvalloEmail author
  • Marlene Alonso-Juarez
Original article
  • 12 Downloads

Abstract

Tremor and parkinsonism are recognized side effects of valproate; however, the relationship between rest tremor and other signs of parkinsonism has not been addressed in patients taking valproate. We studied a cohort of 125 consecutive patients treated with valproate due to epilepsy or migraine, evaluated with the Fahn–Tolosa–Marin Tremor Rating Scale (FTM-TRS). A total of 14 (11.2%) patients had rest tremor (bilateral n = 10, unilateral n = 4). Patients with rest tremor had significant higher scores in the FTM-TRS (P < 0.001), but only one was diagnosed with parkinsonism. Patients may have valproate-induced parkinsonism or exacerbated motor features of Parkinson’s disease by valproate. The frequency of parkinsonism was 1.6% in this cohort and of 3% in the pooled data of 717 patients from previous reports. Rest tremor is observed in 11.2% of patients treated with valproate and is related to the burden of valproate-induced tremor, rather than the presence of parkinsonism.

Keywords

Tremor Drug-induced tremor Valproate Anticonvulsants Parkinsonism 

Notes

Author contributions

JFB: 1A, 1B, 1C, 3A, 3B. MA: 1B, 1C, 3A. [(1) Research project: A. conception, B. organization, C. execution. (2) Statistical analysis: A. design, B. execution, C. review and critique. (3) Manuscript: A. writing of the first draft, B. review and critique.]

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The authors confirm that the approval of the institutional review board was obtained for this work. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Supplementary material

13760_2019_1239_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF (2017) The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord 44:147–150CrossRefGoogle Scholar
  2. 2.
    Stacy MA, Elble RJ, Ondo WG, Wu SC, Hulihan J (2007) TRS study group, assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin tremor rating scale in essential tremor. Mov Disord 22:833–838CrossRefGoogle Scholar
  3. 3.
    Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED (2003) Rest tremor in patients with essential tremor: prevalence, clinical correlates, and electrophysiologic characteristics. Arch Neurol 60:405–410CrossRefGoogle Scholar
  4. 4.
    Alonso-Juarez M, Baizabal-Carvallo JF (2018) Distinguishing features between valproate-induced tremor and essential tremor. Acta Neurol Scand 138:177–181CrossRefGoogle Scholar
  5. 5.
    Morgan JC, Sethi KD (2005) Drug-induced tremors. Lancet Neurol 4:866–876CrossRefGoogle Scholar
  6. 6.
    Hamed SA, Abdellah MM (2017) The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study. Int J Neurosci 127(3):236–242CrossRefGoogle Scholar
  7. 7.
    Zadikoff C, Munhoz RP, Asante AN et al (2007) Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 78:147–151CrossRefGoogle Scholar
  8. 8.
    Ristić AJ, Vojvodić N, Janković S, Sindelić A, Sokić D (2006) The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 47:2183–2185CrossRefGoogle Scholar
  9. 9.
    Armon C, Shin C, Miller P, Carwile S, Brown E, Edinger JD, Paul RG (1996) Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 47:626–635CrossRefGoogle Scholar
  10. 10.
    Easterford K, Clough P, Kellett M, Fallon K, Duncan S (2004) Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 62:1435–1437CrossRefGoogle Scholar
  11. 11.
    Jamora D, Lim SH, Pan A, Tan L, Tan EK (2007) Valproate-induced parkinsonism in epilepsy patients. Mov Disord 22:130–133CrossRefGoogle Scholar
  12. 12.
    Silver M, Factor SA (2013) Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord 19:758–760CrossRefGoogle Scholar
  13. 13.
    Onofrj M, Thomas A, Paci C (1998) Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 245:794–796CrossRefGoogle Scholar
  14. 14.
    Gale K (1986) Role of the substantia nigra in GABA-mediated anticonvulsant actions. Adv Neurol 44:343–364PubMedGoogle Scholar
  15. 15.
    Tepper JM, Lee CR (2007) GABAergic control of substantia nigra dopaminergic neurons. Prog Brain Res 160:189–208CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  1. 1.University of GuanajuatoGuanajuatoMexico
  2. 2.National Polytechnic InstituteMéxicoMexico

Personalised recommendations